Ainos and BioPhoenix Sign VELDONA License Agreement, Establishing a Potential $10 Million Collaboration Framework

HOUSTON, TX / ACCESS Newswire / September 24, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced that it has entered into a VELDONA(®) License Agreement with BioPhoenix Co., Ltd. ("BioPhoenix"), establishing a collaboration framework with a potential aggregate value of $10 million. The framework comprises an initial license fee, conditional consideration for licenses covering 15 additional indications, and a one-time fee upon the first sublicense.

The agreement marks a significant milestone for VELDONA by establishing a partner-funded development model. BioPhoenix will assume primary funding and execution responsibilities for the clinical and regulatory development activities allocated to it under the agreement for the two initial licensed indications, while Ainos retains core platform ownership and long-term commercial interests. Development expenditures funded by BioPhoenix, potential product supply revenue and downstream revenue sharing are separate from, and are not included in, the $10 million collaboration framework.